Climb Bio, Inc. (CLYM) vs MiMedx Group, Inc (MDXG)

Climb Bio, Inc. and MiMedx Group, Inc are both Biotechnology companies. Climb Bio, Inc. and MiMedx Group, Inc are of similar size ($686.5M and $682.9M). Climb Bio, Inc. has negative trailing earnings, so its P/E is not meaningful; MiMedx Group, Inc trades at 117×. MiMedx Group, Inc has the higher net margin (1.76% vs 0.00%) and the higher return on invested capital (5.62% vs −71.7%). Across the 13 metrics below, MiMedx Group, Inc leads on 10 and Climb Bio, Inc. on 3.

Valuation

Metric CLYM MDXG Biotechnology median
P/E n/m 116.75 7.88
P/S n/m 1.94 11.47
P/B 3.71 3.20 2.52
Price to free cash flow n/m 15.53 21.16
EV/EBITDA n/m 28.01 0.74
EV/Sales n/m 1.61 10.73
Earnings yield (7.12%) 0.86% (28.84%)
Free cash flow yield (5.99%) 6.44% (23.03%)

Profitability

Metric CLYM MDXG Biotechnology median
Gross margin — 78.85% 65.16%
Operating margin 0.00% 2.46% 0.00%
Net margin 0.00% 1.76% 0.00%
Free cash flow margin 0.00% 12.51% 0.00%
Return on equity (27.10%) 2.88% (57.72%)
Return on assets (26.27%) 2.18% (49.22%)
Return on invested capital (71.73%) 5.62% 0.00%

Growth

Metric CLYM MDXG Biotechnology median
Revenue growth (TTM) — (2.36%) 5.64%
EPS growth (last fiscal year) 42.48% 14.29% —
Revenue growth, 5-year CAGR — 11.02% 8.40%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric CLYM MDXG Biotechnology median
Debt to equity 0.00 0.08 0.00
Current ratio 31.45 5.33 4.73
Net debt to EBITDA 1.44 (1.88) 0.96

Dividend

Metric CLYM MDXG Biotechnology median
Dividend yield — — 2.10%
Payout ratio 0.00 0.00 0.00

Size

Metric CLYM MDXG Biotechnology median
Market cap 682.92m 686.53m 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack